Genovis AB

GENO

SE0002485979

Medical Equipment, Supplies & Distribution

Delayed Nasdaq Stockholm Other stock markets 10:15:06 03/06/2024 BST			5-day change	1st Jan Change
38.25 ^SEK	0.00%		+9.13%	-26.44%

05-15	Genovis AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-14	Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement	CI

Genovis AB Appoints Rob Horsefield as Sales & Business Development Manager

November 27, 2018 at 07:51 am

Genovis AB announced that the company its sales and marketing organization at its Lund headquarters and hired Rob Horsefield as Sales & Business Development Manager.

Latest news about Genovis AB

Genovis AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement	03-14	CI
Genovis AB (publ.) Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-15	CI
Genovis AB (publ.) Reports Earnings Results for the Full Year Ended December 31, 2023	02-15	CI
Genovis to Get $1 Million Milestone Payment for Xork Development	02-13	MT
Genovis AB (publ.) Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-15	CI
Genovis AB (publ.) Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/08/23	CI
Genovis Launch Innovative Igm-Specific Protease with Wide-Ranging Applications in Life Science Markets	02/06/23	CI
Genovis AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2023	16/05/23	CI
ArcticZymes Technologies ASA and Genovis AB Announce Collaboration to Speed Up Penetration and Growth in the Chinese Market	03/05/23	CI
Genovis AB (publ.) Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	15/02/23	CI
Genovis AB (publ.) Reports Earnings Results for the Full Year Ended December 31, 2022	15/02/23	CI
Genovis AB (publ.) Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/11/22	CI
Genovis AB (publ.) Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/08/22	CI
Genovis Signs Supply Agreement With US Biotech Company; Shares Rise 7%	10/08/22	MT
Genovis AB Enters Licensing and Supply Agreement with New Bioprocess Customer	10/08/22	CI
Genovis Starts Service Agreement with Swiss Biotech Company evitria	04/08/22	MT
Genovis AB Enters Service Agreement with Evitria Ag for Fast LC_MSlysis of Recombinant Antibodies	04/08/22	CI
Genovis AB (Publ.) Announces Board Changes	12/05/22	CI
Genovis AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2022	27/04/22	CI
Genovis AB (publ.) Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	08/02/22	CI
Genovis AB (publ.) Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	12/11/21	CI
Genovis AB Announces Exclusive License Agreement with Selecta Bioscience to Develop and Promote A Novel Igg Protease in Gene Therapy and Autoimmune Disease	21/10/21	CI
Genovis' : New CFO To Assume Role January 2022	06/10/21	MT
Genovis AB (Publ.) Hires Magnus Långberg as the New CFO	06/10/21	CI

Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

Sector

Medical Equipment, Supplies & Distribution

Calendar

20/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Genovis AB

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

38.25 SEK

Average target price

51.5 SEK

Spread / Average Target

+34.64%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
GENOVIS AB	-26.44%	238M
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-3.17%	8.22B
DIASORIN S.P.A.	+6.52%	5.72B
LANTHEUS HOLDINGS, INC.	+31.98%	5.67B
AUTOBIO DIAGNOSTICS CO., LTD.	-10.03%	4.11B
10X GENOMICS, INC.	-59.94%	2.68B
ANDON HEALTH CO., LTD.	+11.23%	2.68B
VITROLIFE AB	-5.19%	2.37B
MYRIAD GENETICS, INC.	+18.91%	2.06B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-7.56%	1.8B

Diagnostic & Testing Substances

Genovis AB

Equities

GENO

SE0002485979

Medical Equipment, Supplies & Distribution

Genovis AB Appoints Rob Horsefield as Sales & Business Development Manager

Latest news about Genovis AB

Chart Genovis AB

Company Profile

Income Statement Evolution

Ratings for Genovis AB

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Diagnostic & Testing Substances